/ Solutions / Drug Research and Development Solutions / Biomarker Discovery
Disease biomarker is a molecule that indicates changes in the physiology of a cell under diseased state
and hence can be used as a diagnostic tool, therapy guidance and prognosis monitoring of diseases. For
most common cell types and corresponding tumors there are no available antibodies in clinical
diagnostics. The demand for new biomarkers is apparent in most areas of pathology and particularly
within the field of cancer diagnostics. It is believed that the combination of liquid biomarker biopsy and AI
technology will inevitably improve the accuracy of biomarker discovery.
Proteomics play an important role in drug development, relying on completion and annotation of the
human genome and new refinements in the techniques to study proteins on the large scale, which has
been applied to gain a better understanding of disease pathogenesis, to discover new and reliable
biomarkers for early detection of diseases and to accelerate drug development. Traditional techniques
include two dimensional polyacrylamide gel electrophoresis
(2-DE), mass spectrometry (MS), protein chip technology, phage display, activity based assays, two
hybrid assays, isotope coded affinity tagging (ICAT) and multidimensional protein identification
technique (MudPIT), and liquid chromatography/mass spectrometry (LC/MS).
In silico Approaches
Development of an in silico framework that is based on re-utilization of pre-existing epidemiologic and
genetic data and that is aimed to identify candidate biomarkers indicative of diseases.
Data collection (publicly available database). Human Protein Atlas (HPA) program
(www.proteinatlas.org) can be used to view protein profiles in a “gene/protein-specific” manner.
Create annotation database. Annotation is performed after immunohistochemical staining, defining cell
populations present in the diffe